Clinical Trial Update: An Extension to Study MD7108240 [Phase 2]

View source ↗

Summary

An extension of the Phase 2 study MD7108240 for macular degeneration by GlaxoSmithKline has completed, with results posted on 2017-12-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• MD7108240

Snippet

Sponsor: GlaxoSmithKline | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2017-12-05